Press Releases - Media - Laekna

Media

Press center

SCROLL DOWN

*All pictures are taken at Laekna offices

Press Releases

Press Releases

June 24, 2026

Update on LAE118 Ex-China Licensing | Laekna Received the Upfront Payment from Vasque Bio

More
June 10, 2026

Voluntary Announcement | Exclusive License Agreement with Vasque Bio for LAE118 (a novel PI3Kα pan-mutant selective inhibitor) in Ex-China Region

More
April 15, 2026

Positive Topline Results | Laekna’s Phase III Clinical Trial of LAE002 (afuresertib) for Breast Cancer Met Primary Endpoint

More
April 13, 2026

Laekna Releases 2025 ESG Report: Advancing Steadily into Commercialization

More
March 19, 2026

Laekna, Inc. (2105.HK) Announces the Consolidated Annual Results 2025

More
March 10, 2026

Positive Topline Results from U.S. Phase I SAD Study of LAE102 Showed Encouraging Trends toward Lean Mass Increase and Fat Mass Reduction

More
February 12, 2026

Nature Communications, February Issue | Afuresertib Plus Fulvestrant Was Well Tolerated and Had Promising Anti-Tumor Activities Against Pretreated, Advanced HR-positive, Her2-negative Breast Cancer

More
January 14, 2026

A Novel PI3Kα Pan-Mutant Selective Inhibitor | Laekna Announced FDA Acceptance of Investigational New Drug Application for LAE118

More

<1 2 3 >

List is empty

x

RSS Subscription

To stay informed about Laekna, fill out the form below to subscribe.

关注来凯医药领英公众号